INSIGHT BANK · 28 LIVING CARDS
Follow a question.
See what changes.
Evidence, technologies, people and the next test—connected, but not confused.
Commercializationv3 · 09.07
Where might linked diagnostic and therapy approvals stall in practice?
Concurrent approvals. Uptake and payment for the new use remain open.
- ✓Drug & CDxRecorded
- ?UptakeUnverified
- ?PaymentUnverified
- ?Real-world useUnverified
Analysis addedAdded a short reading on treatment-switch timing, ongoing monitoring and the practical and payment conditions for adoption.
NEXT CHECKConfirmatory trials, payer policies for the new use and clinical uptake.
Commercializationv2 · 10.13
How are costs, rights and returns shared when another company’s technology enables a treatment?
The partnership and combination-development record now includes BNT113. In HPV16-positive head and neck cancer, the pembrolizumab combination did not establish PFS superiority; assessment of OS, the other prespecified primary endpoint, continues.
- ✓PFS result announcedRecorded
- ?Prespecified OS assessmentUnverified
- ?Detailed resultsUnverified
Additional source checkedAdded the BNT113 PFS result and continuation of the prespecified OS assessment.
NEXT CHECKThe planned OS analysis, detailed PFS results, and explanations of the population and safety findings.
Commercializationv1 · 10.13
What benefit comes from detecting a resistance mutation and switching treatment before radiographic progression?
European certification was added for Guardant360 CDx. Earlier switching prolonged PFS in selected SERENA-6 patients, while SERENA-4 under different conditions missed its primary endpoint. FDA requires confirmation comparing early switching with switching at progression.
- ✓PFS benefit in selected patientsRecorded
- ?Compare early and progression-time switchingUnverified
- ?Long-term benefit and uptakeUnverified
New question openedLinked European CDx certification, SERENA-6, SERENA-4 and FDA confirmation requirements through the question of treatment timing.
NEXT CHECKComparison of early and post-progression use of the same drug, longer-term survival and uptake in the indicated population.